4931431F19Rik Inhibitors
Chemicals classified as Ubqln5 Inhibitors are generally inhibitors of the ubiquitin-proteasome system and do not target Ubqln5 directly. These compounds can influence Ubqln5 indirectly by inhibiting the degradation of proteins that Ubqln5 may be associated with. For example, proteasome inhibitors like MG132, Lactacystin, Bortezomib, Carfilzomib, and Velcade can lead to the accumulation of polyubiquitinated proteins, which may affect the function of Ubqln5 as it is involved in the delivery of substrates to the proteasome.
Furthermore, inhibitors like MLN4924 that target upstream processes such as neddylation can also affect the activity of the proteasome and thus, the function of Ubqln5. Similarly, IU1, which targets deubiquitinating enzymes like USP14, can alter the dynamics of protein degradation, influencing Ubqln5 activity. The role of Ubqln5 in protein quality control means that any compound affecting proteasome function or associated regulatory processes can have a downstream impact on Ubqln5.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can lead to increased levels of ubiquitinated proteins, potentially affecting Ubqln5 function due to altered proteasome activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An irreversible proteasome inhibitor that can disrupt the degradation of polyubiquitinated proteins, potentially impacting Ubqln5 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A dipeptidyl boronic acid derivative that inhibits the 26S proteasome, potentially affecting Ubqln5's role in protein degradation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An epoxyketone-based proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, potentially affecting Ubqln5 function. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An orally bioavailable proteasome inhibitor that can affect the degradation pathway of proteins, potentially impacting Ubqln5's role. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
An inhibitor of NEDD8-activating enzyme, affecting the neddylation pathway which can modulate proteasome activity and potentially Ubqln5's function. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
A specific inhibitor of the deubiquitinating enzyme USP14, which can affect proteasome-associated deubiquitination, potentially impacting Ubqln5. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor that can lead to an accumulation of ubiquitinated proteins, potentially influencing Ubqln5's function. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
A steroidal lactone that can inhibit proteasomal activity, potentially affecting Ubqln5 by disrupting protein degradation. | ||||||